Please use this identifier to cite or link to this item:
|Title:||A European spectrum of pharmacogenomic biomarkers : implications for clinical pharmacogenomics|
Fenech, Anthony G.
Loukas, Yiannis L.
Stubbs, Andrew P.
Schaik, Ron H. van
Wakil, Salma M.
Zompo, Maria del
Lee, Ming Ta Michael
Mc Leod, Howard L.
Spek, Peter J. van der
Patrinos, George P.
Drugs -- Effectiveness
|Citation:||Mizzi., C, Dalabira, E., Kumuthini, J., Dzimiri,N., Balogh, I., Basak, N.,...Patrinos, P. (2016). A European spectrum of pharmacogenomic biomarkers : implications for clinical Pharmacogenomics. PLoS ONE, 11(9), E0162866.|
|Abstract:||Pharmacogenomics aims to correlate inter-individual differences of drug efficacy and/or toxicity with the underlying genetic composition, particularly in genes encoding for protein factors and enzymes involved in drug metabolism and transport. In several European populations, particularly in countries with lower income, information related to the prevalence of pharmacogenomic biomarkers is incomplete or lacking. Here, we have implemented the microattribution approach to assess the pharmacogenomic biomarkers allelic spectrum in 18 European populations, mostly from developing European countries, by analyzing 1,931 pharmacogenomics biomarkers in 231 genes. Our data show significant interpopulation pharmacogenomic biomarker allele frequency differences, particularly in 7 clinically actionable pharmacogenomic biomarkers in 7 European populations, affecting drug efficacy and/or toxicity of 51 medication treatment modalities. These data also reflect on the differences observed in the prevalence of high-risk genotypes in these populations, as far as common markers in the CYP2C9, CYP2C19, CYP3A5, VKORC1, SLCO1B1 and TPMT pharmacogenes are concerned. Also, our data demonstrate notable differences in predicted genotype-based warfarin dosing among these populations. Our findings can be exploited not only to develop guidelines for medical prioritization, but most importantly to facilitate integration of pharmacogenomics and to support pre-emptive pharmacogenomic testing. This may subsequently contribute towards significant cost-savings in the overall healthcare expenditure in the participating countries, where pharmacogenomics implementation proves to be cost-effective.|
|Description:||Acknowledgments: The Euro-PGx project was partly funded by European grant (RD-Connect; FP7-305444) and the Golden Helix Foundation and encouraged by the Genomic Medicine Alliance Pharmacogenomics Working group. The Lithuanian segment of the project was supported by the LITGEN project (VP1-3.1-ŠMM-07-K-01-013), funded by the European Social Fund under the Global Grant Measure. The Czech segment of the project was supported by 00064203, LN14073, LM2015091, NF-CZ11-PDP-3-003-2014 and CZ.2.16/3.1.00/24022OPPK grants to MM. JK was funded by the National Institutes of Health Common Fund Award NHGRI Grant Number U41HG006941. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors declare no conflict of interests.|
|Appears in Collections:||Scholarly Works - FacM&SPat|
Files in This Item:
|A European spectrum of pharmacogenomic biomarkers_implications for clinical pharmacogenomics.pdf||1.72 MB||Adobe PDF||View/Open|
Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.